Bio­gen sees more than 330 de­par­tures from MA-based sites since last sum­mer

The de­cline and fall of Bio­gen’s con­tro­ver­sial Alzheimer’s drug Aduhelm ⁠— from snap ap­proval to pay­er cov­er­age de­nials and now a re­quire­ment for more da­ta — has led the com­pa­ny to aban­don the drug, and cut staff over the past year, in­clud­ing 331 de­par­tures from its Mass­a­chu­setts-based sites.

The lay­offs in Cam­bridge and We­st­on, first re­port­ed by the Boston Busi­ness Jour­nal, are part of $1 bil­lion in over­all cuts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER